Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
about
Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirusFavorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"Comparisons of CD8+ T Cells Specific for Human Immunodeficiency Virus, Hepatitis C Virus, and Cytomegalovirus Reveal Differences in Frequency, Immunodominance, Phenotype, and Interleukin-2 ResponsivenessPredicting population coverage of T-cell epitope-based diagnostics and vaccines.CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects.Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialProgrammed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus diseaseHigh throughput T epitope mapping and vaccine developmentA Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8+ T Cells Essential for the Protection against ExpeIn silico identification of common epitopes from pathogenic mycobacteria.Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native AfricansPrevention of cytomegalovirus disease in recipients of allogeneic stem cell transplantsSequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.Cross-presentation of HCMV chimeric protein enables generation and measurement of polyclonal T cells.Identification and validation of T-cell epitopes in outer membrane protein (OMP) of Salmonella typhi.Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance.Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations.Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation.Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.
P2860
Q21092179-03BBDF34-C240-4E46-ACA3-944F60ED613CQ24673636-E0FCAFF0-3C40-4EAB-B478-D60451295EFFQ24814428-B1902294-8172-46D4-A069-1CC2D319A626Q27487966-79A57D33-B2D3-485D-BFDA-3EB3D9E8FD62Q33236900-456A6978-90DE-4726-9C02-5468EE9EDA6CQ33280303-58FA46DD-25FE-445D-AECD-9AF7C0A70852Q33429827-C1D5B8B5-FF61-4534-B45C-E47AA8166374Q33523611-1EC504C1-2C4A-4E9A-812A-76CFFFE97DDCQ33628719-A77A4E51-9BCA-4DE2-B742-B21754B2B713Q33790313-B164F5AB-1B77-4375-883A-9BFF31AAB965Q34607617-EE37C697-E0EF-4487-AAA5-1771AEEAB5FBQ34651577-5CE38522-43A6-4946-979D-2FD98F5C2552Q35558815-DB5CC267-B6C4-4370-A200-FCEC0A4F1248Q35818040-4C99FE85-447A-43CE-9505-7FAAD4869AC3Q35842287-ACB0288F-23C7-4941-8B8B-C207663A3BF8Q36824066-A1CA51C8-F1D4-4378-9E86-E4DD06D96085Q36960608-DB95BA82-1AFA-4370-9A90-917FBEDEF0EBQ39895985-24E0319B-1A0A-44C4-95D2-EE0C63AF42DEQ41725375-7A31961E-EE95-4081-80C3-D7B98927A2C9Q42938727-B6AA28D1-4435-4DFC-BC35-EA5AC5FABCEEQ43430617-293636B3-044E-4F89-822A-DDF4B8C65A1BQ47099267-54A309CA-FBB0-42D3-80C8-2AD5E85B1E1FQ53660426-D12A2A7E-7F95-431E-A1F1-6996E857E307Q55259946-C6E344DF-0DF7-462B-9B16-DC5A35473943
P2860
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
@en
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
@nl
type
label
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
@en
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
@nl
prefLabel
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
@en
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
@nl
P2093
P356
P1433
P1476
Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes
@en
P2093
P2888
P304
P356
10.1007/S002510000271
P407
P577
2001-01-01T00:00:00Z